Milestone Pharmaceuticals (NASDAQ:MIST) Rating Lowered to “Hold” at TD Securities

Milestone Pharmaceuticals (NASDAQ:MIST) was downgraded by investment analysts at TD Securities from a “buy” rating to a “hold” rating in a research report issued on Tuesday,BayStreet.CA reports.

Separately, HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of Milestone Pharmaceuticals in a report on Friday.

Milestone Pharmaceuticals Stock Down 4.8 %

Shares of NASDAQ:MIST traded down $0.04 during trading on Tuesday, hitting $0.76. The company’s stock had a trading volume of 3,585,980 shares, compared to its average volume of 698,361. The business has a 50 day moving average price of $1.97 and a two-hundred day moving average price of $1.83. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40. Milestone Pharmaceuticals has a fifty-two week low of $0.72 and a fifty-two week high of $2.75. The company has a market capitalization of $40.66 million, a PE ratio of -0.94 and a beta of 1.83.

Institutional Investors Weigh In On Milestone Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Jones Financial Companies Lllp grew its stake in shares of Milestone Pharmaceuticals by 1,000.0% in the 4th quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock valued at $26,000 after purchasing an additional 10,000 shares during the last quarter. Virtu Financial LLC purchased a new position in Milestone Pharmaceuticals during the 4th quarter worth $170,000. PVG Asset Management Corp acquired a new stake in shares of Milestone Pharmaceuticals in the 3rd quarter worth $46,000. Northern Trust Corp increased its stake in shares of Milestone Pharmaceuticals by 112.6% during the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company’s stock worth $137,000 after acquiring an additional 30,772 shares during the period. Finally, Toronto Dominion Bank purchased a new position in Milestone Pharmaceuticals during the fourth quarter worth about $1,770,000. 86.18% of the stock is owned by hedge funds and other institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.